Q-omics provides the consensus-scored ALKBH5 profile across patient tissues and cancer cell-line models. ALKBH5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ALKBH5 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ALKBH5 protein abundance shows 22,128 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, KIRC, and GBM as cancer lineages where ALKBH5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALKBH5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALKBH5 survival associations across molecular data types. ALKBH5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALKBH5 RNA expression–survival associations across cancer types. High ALKBH5 expression shows unfavorable associations in KICH, BLCA, HNSC, ACC and LGG, but favorable associations in SCLC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for ALKBH5 RNA expression.
This table summarizes ALKBH5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ALKBH5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALKBH5 shows lower tumor expression in KICH, THCA and READ and higher tumor expression in KIRC, HNSC and LIHC. The KIRC box plot shows higher ALKBH5 RNA expression in tumor versus normal tissue (log2 FC = +0.641, t-test p < 0.001).
This table shows molecular features associated with ALKBH5 in patient tissues and cancer cell lines. In patient samples, ALKBH5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ALKBH5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
